Open AccessClinical Impact and Cost-Effectiveness of Making Third-Line Antiretroviral Therapy Available in Sub-Saharan Africa
Author(s) -
Éric Ouattara,
E. Clarke Ross,
Yazdan Yazdanpanah,
Angela Y. Wong,
Marion Robine,
Elena Losina,
Raoul Moh,
Rochelle P. Walensky,
Christine Danel,
A. David Paltiel,
Serge Eholié,
Kenneth A. Freedberg,
Xavier Anglaret
Publication year - 2014
Publication title -
journal of acquired immune deficiency syndromes
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.162
H-Index - 157
eISSN - 1944-7884
pISSN - 1525-4135
DOI - 10.1097/qai.0000000000000166
Subject(s) - raltegravir , regimen , medicine , cost effectiveness , second line , per capita , antiretroviral therapy , human immunodeficiency virus (hiv) , first line , viral load , family medicine , environmental health , risk analysis (engineering) , population
In sub-Saharan Africa, HIV-infected adults who fail second-line antiretroviral therapy (ART) often do not have access to third-line ART. We examined the clinical impact and cost-effectiveness of making third-line ART available in Côte d'Ivoire.